Copyright © 2011 Research To Practice. All rights reserved. What Clinicians Want to Know A Live CME Event Addressing the Most Common Questions and Controversies in the Current Clinical Management of Select Hematologic Cancers Sunday, June 5, :00 PM – 9:30 PM Chicago, Illinois Faculty Sergio Giralt, MD John P Leonard, MD Lauren C Pinter-Brown, MD Moderator Neil Love, MD Antonio Palumbo, MD Susan M O’Brien, MD Professor Michael Hallek

Copyright © 2011 Research To Practice. All rights reserved. Agenda Module 1 – Dr Giralt: Multiple Myeloma (MM) in the Transplant Setting Module 2 – Dr Leonard: Follicular Lymphoma (FL), Transformation and Diffuse Large B-Cell Lymphoma (DLBCL) Module 3 – Dr Pinter-Brown: Peripheral and Cutaneous T-Cell Lymphomas (PTCL and CTCL) and Mantle-Cell Lymphoma (MCL) Module 4 – Dr Palumbo: Multiple Myeloma in the Nontransplant Setting Module 5 – Dr O’Brien: Chronic Myeloid Leukemia (CML) Module 6 – Prof Hallek: Chronic Lymphocytic Leukemia (CLL)

Copyright © 2011 Research To Practice. All rights reserved. Survey of Oncologists General survey assessing interest level in clinical topics related to the treatment of hematologic neoplasms (April 15-28, 2011) 100 community-based medical oncologists who treat hematologic oncology in the US Percent of practice that is solid tumors (median) 69% Percent that is hematologic oncology (median)31%

Copyright © 2011 Research To Practice. All rights reserved. Survey of Oncologists Median number of new patients seen per year with… Multiple myeloma15 Follicular lymphoma20 Diffuse large B-cell lymphoma15 T-cell lymphoma4 Mantle-cell lymphoma5 Chronic myeloid leukemia6 Chronic lymphocytic leukemia20

Copyright © 2011 Research To Practice. All rights reserved. If you were to attend a CME conference on hematologic oncology, to what extent would you be interested in learning about the following topics? Response scale 0 – 10 0 = no interest 10 = very interested Survey of Oncologists

Copyright © 2011 Research To Practice. All rights reserved. Multiple Myeloma: Cytogenetics and FISH in Clinical Decision-Making 0% 2% 4% 8% 4% 11% 16% 23% 30% 0%5%10%15%20%25%30%35% = very interested 0 = no interest 53%

Copyright © 2011 Research To Practice. All rights reserved. Multiple Myeloma: Method of Transplant (Auto, Allo, Tandem) 4% 5% 8% 10% 11% 18% 10% 13% 9% 7% 5% 0%5%10%15%20%25%30%35% = very interested 0 = no interest 12%

Copyright © 2011 Research To Practice. All rights reserved. What question(s) would you like to pose to a clinical investigator with expertise in the management of hematologic oncology? 1322 questions/cases received Survey of Oncologists

Copyright © 2011 Research To Practice. All rights reserved. Interest in Topics Related to the Treatment of Patients with MM Who Are Transplant Eligible (Percent Responding 9 or 10) 34% 41% 42% 46% 48% 53% 0%10%20%30%40%50%60% Management of side effects Renal dysfunction in MM Delayed/deferred transplant Post-transplant maintenance New agents/regimens Initial therapy for patients <65 yo Cytogenetics and FISH

Copyright © 2011 Research To Practice. All rights reserved. Is there a best pre-transplant induction regimen? Under what clinical circumstances is a triple drug regimen preferred over a double drug regimen for induction? Does SCT still play a role in up-front therapy, or can it be reserved for patients with relapsed multiple myeloma for whom many treatment options have failed? Multiple Myeloma: Transplant Setting

Copyright © 2011 Research To Practice. All rights reserved. Role of ASCT: Single versus tandem transplant 54 yo woman with great performance status (ECOG = 0) and poor-risk cytogenetics who has experienced a VGPR after RVD followed by autoPBSCT. What is the best consolidation therapy — a second autoPBSCT, a mini-alloPBSCT (+ identified matched sibling) or maintenance treatment? Role of maintenance therapy in multiple myeloma Multiple Myeloma: Transplant Setting